KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Depreciation & Amortization (CF) (2020 - 2025)

Aurinia Pharmaceuticals (AUPH) has disclosed Depreciation & Amortization (CF) for 6 consecutive years, with $4.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Depreciation & Amortization (CF) changed 0.04% year-over-year to $4.9 million, compared with a TTM value of $19.4 million through Dec 2025, changed 0.02%, and an annual FY2025 reading of $19.4 million, changed 0.02% over the prior year.
  • Depreciation & Amortization (CF) was $4.9 million for Q4 2025 at Aurinia Pharmaceuticals, roughly flat from $4.9 million in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $5.3 million in Q3 2023 and bottomed at -$6.1 million in Q4 2023.
  • Average Depreciation & Amortization (CF) over 5 years is $2.0 million, with a median of $939500.0 recorded in 2021.
  • The sharpest move saw Depreciation & Amortization (CF) skyrocketed 5633.33% in 2021, then tumbled 223.16% in 2023.
  • Year by year, Depreciation & Amortization (CF) stood at -$1.4 million in 2021, then plummeted by 38.04% to -$1.9 million in 2022, then crashed by 223.16% to -$6.1 million in 2023, then soared by 179.73% to $4.9 million in 2024, then increased by 0.04% to $4.9 million in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for AUPH at $4.9 million in Q4 2025, $4.9 million in Q3 2025, and $4.9 million in Q2 2025.